Navigation Links
FluoroPharma Obtains US Patent for Imaging Cardiovascular Plaque using FDG
Date:1/26/2009

BOSTON, Jan. 26 /PRNewswire/ -- FluoroPharma Inc., a company developing breakthrough molecular imaging agents for the Positron Emission Tomography (PET) market, announced today that the United States Patent and Trademark Office issued U.S. Patent No. 7,438,891, covering methods of imaging cardiovascular plaque formation using F18 labeled 2-fluorodeoxy-D-glucose (FDG). This patent, exclusively licensed from the Massachusetts General Hospital, provides FluoroPharma with additional patent claims that cover imaging of atherosclerotic plaque inflammation and rupture.

"The use of 18F-FDG PET for imaging atherosclerosis, for tracking inflammation within plaque and for monitoring the response to drug therapy is promising and should be part of future diagnostic armament," said Dr. David Elmaleh, FluoroPharma founder and Chief Scientific Advisor.

"Molecular imaging of the inflammatory status of vulnerable atherosclerotic lesions is of paramount importance for the identification of patients at risk for a future heart attack or stroke," said Dr. Tom Brady, Director of Nuclear Medicine and Molecular Imaging Division at the MGH, "In vivo noninvasive clinical studies to measure carotid plaque inflammation show that 18F -FDG PET imaging can identify a subset of patients with carotid atherosclerosis that may benefit from intensified medical therapy or carotid artery intervention to prevent stroke."

"This newly issued patent adds to FluoroPharma's already impressive patent position covering agents for imaging atherosclerotic plaque using PET," said Dr. Kundakovic, President of FluoroPharma, "Our broad technology platform continues to provide FluoroPharma with the ability to develop effective cardiovascular imaging agents for PET market."

About FluoroPharma

FluoroPharma is a molecular imaging company engaged in the discovery and development of proprietary products for the PET market. FluoroPharma is advancing proprietary products for assessment of acute and chronic forms of coronary disease. These agents have been designed to rapidly target either the myocardial cells within the heart or inflamed plaques within the coronary arteries. www.fluoropharma.com

This release may contain forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements reflect, among other things, management's current expectations, plans and strategies, and anticipated financial results, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Many of these risks are beyond our ability to control or predict including the company's need for additional funds, the company's dependence on a limited number of imaging compounds, the early state of the products the company is developing, uncertainties relating to clinical trials and regulatory reviews, competition and dependence on collaborative partners, the company's ability to avoid infringement of the patent rights of others, and the company's ability to obtain adequate patent protection and to enforce these rights. Because of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the date they are made. FluoroPharma does not undertake any obligation to update or review any such forward-looking information, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE FluoroPharma Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. FluoroPharma Inc. Expands Technology Platform to Include Agents for Alzheimers Disease (AD)
2. GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.
3. Patient Lift Manufacturer, Medcare Products, Obtains Women-Owned Certification
4. Aspreva obtains shareholder approval for acquisition by Galenica
5. VIE Healthcare Expands Its Operations in the Midwest, and Obtains First Local Client
6. DRAXIS Obtains Interim Order for Proposed Arrangement
7. DRAXIS Obtains Final Order for Proposed Arrangement
8. China Medicine Corporation Obtains Australian Patent for rADTZ
9. William F. McMurry - Lead Class Counsel Obtains $16.4 Million Settlement for Elderly Clients
10. China Sky One Medical, Inc. Obtains Production Approval for Two New Drugs
11. Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2017)... , ... June 24, 2017 , ... The weather is ... time outdoors. Home and business owners should be aware that the summer months provide ... In fact, mechanical locks and keys can be negatively affected from direct exposure to ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Rhode Island Quality ... Management Alerts and Dashboards, an innovative new service enabling healthcare providers to proactively ... Management Alerts and Dashboards provide near real-time data about patients admitted to and/or ...
(Date:6/23/2017)... , ... June 23, 2017 , ... By scoring 100% ... ninth consecutive four-star rating from premier online charity evaluator, Charity Navigator, validating ANRF's work ... 1% of all charities reviewed by Charity Navigator and earns ANRF a spot on ...
(Date:6/23/2017)... , ... June 24, 2017 , ... Studies show evidence ... reduce the risk of visual loss in these patients. , But how often do ... or smoking cessation to patients at risk of or with early symptoms of AMD? ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... plastic surgeon practicing in Newburgh, New York, has recently begun offering three new ... to offering the best cutting-edge procedures and reducing downtime, Dr. Rubinstein is excited ...
Breaking Medicine News(10 mins):
(Date:6/1/2017)... June 1, 2017 Nutriceutical Holdings (NH), parent ... Solutions (VRS), and KD Pharma Group have decided to ... by KD Pharma Group. KD Pharma Group will become ... to acquire the entire company. "We believe ... are committed to growing the NH companies by providing ...
(Date:5/26/2017)... 26, 2017  Endo International plc (NASDAQ: ENDP ... CEO, will represent the Company in a fireside chat at ... Tuesday, June 13, 2017 at 10:40 a.m. PT / 1:40 ... in Rancho Palos Verdes, CA. ... will be available on the Company,s website at http://www.endo.com/investors/overview ...
(Date:5/22/2017)...  As the specialty pharmacy industry and the ... the revolutionary shift from volume-based to value-based care, ... patient outcomes and shaping the future of the ... from clinical trials and toward data that reveals ... therapy utilization in precise patient populations. Therigy ® ...
Breaking Medicine Technology: